Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) released its quarterly earnings results on Friday. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, Zacks reports.
Titan Pharmaceuticals Stock Performance
Shares of TTNP traded up $0.04 during midday trading on Friday, hitting $3.23. The company had a trading volume of 17,499 shares, compared to its average volume of 19,230. The company’s 50-day simple moving average is $3.74 and its 200-day simple moving average is $4.99. Titan Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $14.80.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on shares of Titan Pharmaceuticals in a report on Friday, December 27th. They issued a “sell” rating on the stock.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- How to Calculate Stock Profit
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- Comparing and Trading High PE Ratio Stocks
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- Profitably Trade Stocks at 52-Week Highs
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
